Pasithea Therapeutics Stock Price, News & Analysis (NASDAQ:KTTA) $0.32 -0.01 (-3.04%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.29▼$0.3250-Day Range$0.30▼$0.4852-Week Range$0.29▼$1.05Volume32,350 shsAverage Volume60,902 shsMarket Capitalization$6.65 millionP/E RatioN/ADividend YieldN/APrice Target$2.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Pasithea Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside527.0% Upside$2.00 Price TargetShort InterestHealthy0.24% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPasithea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, Pasithea Therapeutics has a forecasted upside of 527.0% from its current price of $0.32.Amount of Analyst CoveragePasithea Therapeutics has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.24% of the float of Pasithea Therapeutics has been sold short.Short Interest Ratio / Days to CoverPasithea Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pasithea Therapeutics has recently decreased by 2.46%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPasithea Therapeutics does not currently pay a dividend.Dividend GrowthPasithea Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KTTA. Previous Next 2.1 News and Social Media Coverage News SentimentPasithea Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Pasithea Therapeutics this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders14.10% of the stock of Pasithea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.48% of the stock of Pasithea Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioPasithea Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pasithea Therapeutics Stock (NASDAQ:KTTA)Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Read More KTTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTTA Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNovember 29, 2023 | msn.comPasithea stock jumps 12% on update for anti-tumor drug PAS-004December 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 29, 2023 | markets.businessinsider.comPasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical DevelopmentNovember 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNovember 9, 2023 | finance.yahoo.comPasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSSeptember 14, 2023 | finance.yahoo.comPasithea Therapeutics Corp. Announces Final Results of Tender OfferSeptember 7, 2023 | finance.yahoo.comPasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.August 1, 2023 | finance.yahoo.comPasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor functionJuly 20, 2023 | benzinga.comWhat's Happening With Pasithea Therapeutics Stock Today?July 20, 2023 | finance.yahoo.comPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashJuly 20, 2023 | finance.yahoo.comPasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.July 20, 2023 | finance.yahoo.comPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashJune 30, 2023 | finance.yahoo.comPasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of DirectorsJune 29, 2023 | finance.yahoo.comPasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004June 5, 2023 | barrons.comPasithea Therapeutics Corp.June 1, 2023 | finanznachrichten.deFinancialnewsmedia.com: Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029June 1, 2023 | finance.yahoo.comPasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis ConferenceMay 14, 2023 | finance.yahoo.comPasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022)May 3, 2023 | finance.yahoo.comPasithea Therapeutics to Participate in EF Hutton Inaugural Global ConferenceApril 1, 2023 | seekingalpha.comPasithea Therapeutics files for $15M mixed shelf offeringMarch 2, 2023 | finance.yahoo.comPasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual MeetingFebruary 23, 2023 | finance.yahoo.comPasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)February 16, 2023 | finance.yahoo.comPasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine AwardJanuary 25, 2023 | seekingalpha.comKTTA Pasithea Therapeutics Corp.January 18, 2023 | finance.yahoo.comPasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004See More Headlines Receive KTTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KTTA CUSIPN/A CIK1841330 Webwww.pasithea.com Phone702-514-4174FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$2.00 High Stock Price Target$2.00 Low Stock Price Target$2.00 Potential Upside/Downside+527.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,940,000.00 Net MarginsN/A Pretax Margin-3,436.96% Return on Equity-45.98% Return on Assets-42.91% Debt Debt-to-Equity RatioN/A Current Ratio10.16 Quick Ratio10.16 Sales & Book Value Annual Sales$490,000.00 Price / Sales13.57 Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book0.23Miscellaneous Outstanding Shares20,840,000Free Float17,899,000Market Cap$6.65 million OptionableNot Optionable Beta0.71 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Lawrence Steinman BA (Age 75)M.D., Ph.D., Executive Chairman & Co-Founder Comp: $250kDr. Tiago Reis Marques M.D. (Age 46)Ph.D., CEO & Director Comp: $539.25kMr. Daniel H. Schneiderman (Age 45)Chief Financial Officer Comp: $327.91kDr. Yassine Bendiabdallah Ph.D. (Age 38)COO & Head of UK Clinics Dr. Graeme Currie Ph.D.Chief Development OfficerKey CompetitorsSunshine BiopharmaNASDAQ:SBFMAlterity TherapeuticsNASDAQ:ATHEAlzamend NeuroNASDAQ:ALZNFlora GrowthNASDAQ:FLGCVallon PharmaceuticalsNASDAQ:VLONView All CompetitorsInsidersLawrence SteinmanBought 30,000 shares on 6/2/2023Total: $12,900.00 ($0.43/share)View All Insider Transactions KTTA Stock Analysis - Frequently Asked Questions Should I buy or sell Pasithea Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pasithea Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KTTA shares. View KTTA analyst ratings or view top-rated stocks. What is Pasithea Therapeutics' stock price target for 2024? 1 brokers have issued twelve-month price targets for Pasithea Therapeutics' stock. Their KTTA share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 527.0% from the stock's current price. View analysts price targets for KTTA or view top-rated stocks among Wall Street analysts. How have KTTA shares performed in 2023? Pasithea Therapeutics' stock was trading at $0.6417 at the beginning of the year. Since then, KTTA shares have decreased by 50.3% and is now trading at $0.3190. View the best growth stocks for 2023 here. When is Pasithea Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our KTTA earnings forecast. When did Pasithea Therapeutics IPO? (KTTA) raised $17 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share. How do I buy shares of Pasithea Therapeutics? Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:KTTA) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.